Pulmonary immune responses against SARS-CoV-2 infection: harmful or not?

Intensive Care Medicine

Volumn 46, Issue 10, 2020, Pages 1897-1900

  Guillon, A ^a,b   Hiemstra, P S ^c   Si Tahar, M ^a,b  

^a UNIVERSITÉ DE TOURS   (France)

^b Université Franaois Rabelais   (France)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; RNA;

ARTICLE; CORONAVIRUS DISEASE 2019; HUMAN; HYPERINFLAMMATION; IMMUNE RESPONSE; INNATE IMMUNITY; INTENSIVE CARE UNIT; LUNG PARENCHYMA; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MEDICAL DECISION MAKING; MONOCYTE; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; T LYMPHOCYTE; VIRUS PNEUMONIA; VIRUS REPLICATION; BETACORONAVIRUS; CORONAVIRUS INFECTION; IMMUNE EVASION; PANDEMIC; SEVERE ACUTE RESPIRATORY SYNDROME;

BETACORONAVIRUS; CORONAVIRUS INFECTIONS; HUMANS; IMMUNE EVASION; PANDEMICS; PNEUMONIA, VIRAL; RNA; SEVERE ACUTE RESPIRATORY SYNDROME;

EID: 85087994811     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-020-06170-8     Document Type: Article

References (20)

1. Hou YJ, Okuda K, Edwards CE et al (2020) SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. Cell. 10.1016/j.cell.2020.05.042 DOI: 10.1016/j.cell.2020.05.042
2. Hui KPY, Cheung M-C, Perera RAPM et al (2020) Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures. Lancet Respir Med. 10.1016/S2213-2600(20)30193-4 DOI: 10.1016/S2213-2600(20)30193-4
3. Chu H, Chan JF-W, Wang Y et al (2020) Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19. Clin Infect Dis. 10.1093/cid/ciaa410 DOI: 10.1093/cid/ciaa410
4. Kikkert M (2020) Innate immune evasion by human respiratory RNA viruses. J Innate Immun 12:4–20. 10.1159/000503030 DOI: 10.1159/000503030
5. Yang Y, Shen C, Li J et al (2020) Exuberant elevation of IP-10, MCP-3 and IL-1ra during SARS-CoV-2 infection is associated with disease severity and fatal outcome. medRxiv. 10.1101/2020.03.02.20029975 DOI: 10.1101/2020.03.02.20029975
6. Huang C, Wang Y, Li X et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497–506. 10.1016/S0140-6736(20)30183-5 DOI: 10.1016/S0140-6736(20)30183-5
7. Qin C, Zhou L, Hu Z et al (2020) Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 10.1093/cid/ciaa248 DOI: 10.1093/cid/ciaa248
8. de Jong MD, Simmons CP, Thanh TT et al (2006) Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 12:1203–1207. 10.1038/nm1477 DOI: 10.1038/nm1477
9. Suntharalingam G, Perry MR, Ward S et al (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355:1018–1028. 10.1056/NEJMoa063842 DOI: 10.1056/NEJMoa063842
10. Ferreira M, Blin T, Collercandy N et al (2020) Critically ill SARS-CoV-2-infected patients are not stratified as sepsis by the qSOFA. Ann Intensive Care 10:43. 10.1186/s13613-020-00664-w DOI: 10.1186/s13613-020-00664-w
11. Jouan Y, Guillon A, Gonzalez L et al (2020) Functional alteration of innate T cells in critically ill Covid-19 patients. medRxiv. 10.1101/2020.05.03.20089300 DOI: 10.1101/2020.05.03.20089300
12. Liao M, Liu Y, Yuan J et al (2020) The landscape of lung bronchoalveolar immune cells in COVID-19 revealed by single-cell RNA sequencing. medRxiv. 10.1101/2020.02.23.20026690 DOI: 10.1101/2020.02.23.20026690
13. Bao L, Deng W, Gao H et al (2020) Reinfection could not occur in SARS-CoV-2 infected rhesus macaques. bioRxiv. 10.1101/2020.03.13.990226 DOI: 10.1101/2020.03.13.990226
14. Channappanavar R, Fehr AR, Vijay R et al (2016) Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe 19:181–193. 10.1016/j.chom.2016.01.007 DOI: 10.1016/j.chom.2016.01.007
15. Copin M-C, Parmentier E, Duburcq T et al (2020) Time to consider histologic pattern of lung injury to treat critically ill patients with COVID-19 infection. Intensive Care Med. 10.1007/s00134-020-06057-8 DOI: 10.1007/s00134-020-06057-8
16. Schaller T, Hirschbühl K, Burkhardt K et al (2020) Postmortem examination of patients with COVID-19. JAMA. 10.1001/jama.2020.8907 DOI: 10.1001/jama.2020.8907
17. Chen G, Wu D, Guo W et al (2020) Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Investig. 10.1172/JCI137244 DOI: 10.1172/JCI137244
18. Diao B, Wang C, Tan Y et al (2020) Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). medRxiv. 10.1101/2020.02.18.20024364 DOI: 10.1101/2020.02.18.20024364
19. Wang X, Xu W, Hu G et al (2020) SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion. Cell Mol Immunol. 10.1038/s41423-020-0424-9 DOI: 10.1038/s41423-020-0424-9
20. Xiong Y, Liu Y, Cao L et al (2020) Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg Microbes Infect 9:761–770. 10.1080/22221751.2020.1747363 DOI: 10.1080/22221751.2020.1747363